David Vysosky

Neurologist with interest in #biotech, #glioblastoma, and oncolytic virotherapy, all things NK cells, and Kieslowski's films--especially The Trilogy.

[David Vysosky @davidal156]

@Filmnoir11 @Stephengm99 @aria606 @EricTopol @sailorrooscout We know the Israeli data is more robust and meaningful because unlike the UK or the US, they vaccinated first--in December and they keep granular records, unlike the US. I'm a doctor who was vaccinated months ago. I don't like the way the booster issue is being handled here.

[David Vysosky @davidal156]

@Filmnoir11 @Stephengm99 @aria606 @EricTopol @sailorrooscout Your tweets are factual; however, the issue is not vaccine efficacy, it's waning efficacy. Not only does the granular Israeli data show waning efficacy... it also shows that boosters work quite well to boost this waning immunity in terms of severe outcomes.

[David Vysosky @davidal156]

@rdaily Happy for you, Doc. Hopefully will score a hit from my dealer in the near future as well.

[David Vysosky @davidal156]

@AdamSinger I agree, but, I think her pregnancy could sway some male jurors to be sympathetic to her plight. This shouldn't happen, but it might.

[David Vysosky @davidal156]

@brandonhicks @ARAdultImmDoc Very good points. Do you risk potential side effects with a third Pfizer booster that moves the needle only slightly versus a distinct booster that is updated for variants of concern.

[David Vysosky @davidal156]

@brandonhicks Problem with an updated vaccine, tailor made for the delta strain, is Delta might be gone in 4 months, displaced by a new variant; doesn't it make sense to boost now with a third mRNA shot, hoping increased antibodies can fend off the Delta...esp. in aged/immune suppressed?

[David Vysosky @davidal156]

@MichaelodwyerMD @EricVivier1 I suspect this is the case for the most robust effect... MDACC-AFM13 data suggests this is the case as does preclinical data looking at AFM24 in solid tumors with added NK cells.

[David Vysosky @davidal156]

@GZuckerman @adamfeuerstein @bradloncar Sadly, most people view Biogen's FDA approval as unambiguous proof there is an effective treatment for Alzheimer's Disease. My office has already been contacted by several families wanting the infusions for their parents.

[David Vysosky @davidal156]

https://t.co/YLLGrzLNQt

[David Vysosky @davidal156]

@Long6422Da @dhovekamp42 @biosleuth 1 was the older NK version, and, one, if memory is correct, was a T-cell bispecific targeting EGFR. Differences I believe involved potency and, more important, half life. T-cell research outlined here: https://t.co/VIoQdP5KQe

[David Vysosky @davidal156]

@dhovekamp42 Congrats Dieter!

[Everything SpaceX @spacex360]

@elonmusk ‘The Starship Has Landed’

[Elon Musk @elonmusk]

Starship landing nominal!

[David Vysosky @davidal156]

@Orangeman1992 @marketreader8 @dhovekamp42 Wonder what you guys think about $ALEC. I'm very intrigued by their Alzheimer's approach, but it's very early and very risky, I have a tiny, tiny position. I love their science--and neurodegenerative disease may be where oncology was prior to the first immune oncology drug.

[David Vysosky @davidal156]

@Orangeman1992 @marketreader8 @dhovekamp42 Lastly, there is a discount in that it is essentially targeting a new angle in immune oncology. It's doing something that really no one else is doing(to date), so it's harder to measure, harder to value.

[David Vysosky @davidal156]

@Orangeman1992 @marketreader8 @dhovekamp42 Well said. There is both a Europe as well as CEO/Adi discount. It was undervalued at 1.80 a share and it's undervalued today. My key take away is it will one day(soon hopefully)be fairly valued.

[David Vysosky @davidal156]

@ZachPharmD @sentivcapital @BayAreaBiotechI @STL_Biotech @XBIObserver Also seeing PR's and CR's with monotherapy in T-cell lymphoma with ongoing trial with AFM13, and monotherapy at a small Columbia trial with AFM13 in cutaneous lymphoma. https://t.co/ShaAANpege. Any CD30 lymphoma might benefit from the MD Anderson--Affimed approach.

[David Vysosky @davidal156]

@dhovekamp42 @xlp007 @PersimmonTI @MattBiotech @RNA_Biotech @RNAiAnalyst @LuciusJameson @jfais20 @8thKingofRome Great minds think alike =)

[David Vysosky @davidal156]

@xlp007 @dhovekamp42 @PersimmonTI @MattBiotech @RNA_Biotech @RNAiAnalyst @LuciusJameson @jfais20 @8thKingofRome AFM12 was discarded back in the day and AFM11 the T cell bispecific twin of AFM12 was developed, but with the MD Anderson news, I wonder if something like AFM12 would have a new future for refractory CD19 cancers.

[David Vysosky @davidal156]

@xlp007 @dhovekamp42 @PersimmonTI @MattBiotech @RNA_Biotech @RNAiAnalyst @LuciusJameson @jfais20 @8thKingofRome For reference, AFM12 is a NK bispecific, binds NK-cells via CD16A with a second binding site to CD19. AFM12 focuses the NK-cells to CD19 expressing cancer cells and binds both targets, establishing a bridge, whereby the NK-cells are activated to kill cancer cells.